A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Exclusion Criteria

• •Participants who have developed an AE while participating in the Parent Study. which, in the opinion of the Investigator or of the Medical Monitor, could indicate that continued treatment with APG777 may present an unreasonable risk for the patient
• •Participants who terminated early from the Parent Study or permanently discontinued the study drug during the Parent Study
• •Use of any of the prohibited medications in the Parent Study through Screening Visit (Visit 1) of the LTE study
• •Presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of AD and/or interfere with study assessments